BioSpace News Archive

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Medical Officer, Douglas W. Losordo, M.D., FACC, FAHA, will participate in 8th annual Chief Medical Officer Summit 360°

Telo Genomics Corp. (TSX-V: TELO) (OTC: TDSGF) (the “Company” or “TELO”) is pleased to announce that it has engaged Leede Jones Gable Inc. and Mackie Research Corporation (the “Brokers”) to solicit and facilitate, on a commercially reasonable efforts basis, the exercise of warrants issued pursuant to the Company’s financing announced November 25th, 2019 (the “Warrants”).

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the presentation of data from clinical studies of its once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis and in women with uterine fibroids

Sechrist Veterinary Health, a leading manufacturer of Hyperbaric Oxygen Therapy chambers for veterinary specific applications, has launched a Clinical Advisory Board to help raise clinical awareness and extend the benefits of hyperbaric oxygen therapy to the veterinary medical community.

PharmaEssentia Corporation (TPEx: 6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the appointment of Raymond Urbanski, M.D., Ph.D., as Head of Clinical Development and Medical Affairs for the U.S. subsidiary.

RareMed Solutions announces that it has been selected by PTC Therapeutics, Inc. to provide non-commercial dispensing services for the drug EMFLAZA® (deflazacort).

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that members of management will participate in the Virtual Investor KOL Roundtable on Tuesday, October 27, 2020 at 12:00 PM ET. Participating in the KOL Roundtable discussion will be Paula Brown Stafford, Chairman and Chief Executive Officer of Novan and Carri Geer, SVP, Chief Technology Officer of Novan. Joining the Novan Management team for the roundtable will be John

According to recent surveys, nearly 50% of Americans say they are unlikely to get a COVID-19 vaccine when it becomes available. The main reasons cited are concerns about potential negative side effects and a lack of trust and transparency in the approval process

The Pew Charitable Trusts announced today that Merck & Co. Inc. (known as MSD outside the U.S. and Canada ) and Kyorin Pharmaceutical Co. Ltd. ( Japan ) have shared antibiotic research data on Pew’s open-access Shared Plat

Crown Aesthetics , a division of Crown Laboratories, Inc. and pioneers in advanced aesthetics solutions, sheds light on their dedication to patients’ safety following the decision to move all production of ProGen PRP TM , their FDA 510k cleared Platelet Rich Plasma system, to a manufacturing facility in the United States as of December